iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Biocon joins hands with Biomm to commercialize diabetes drug in Brazil

18 Apr 2024 , 11:06 AM

Biotechnology business Biocon said on Wednesday that it has entered into an agreement with Brazil-based Biomm SA to commercialise its diabetic treatment in the Latin American nation. Under the terms of the partnership, Biocon will develop, manufacture, and deliver Semaglutide (gOzempic), while Biomm will be in charge of getting regulatory approval and marketing in Brazil.

Biomm’s Nova Lima production facility is dedicated to the development, manufacture, and commercialization of complex biotech and biosimilar medicinal products.

Siddharth Mittal, Biocon’s CEO and MD, emphasized the significance of the collaboration with Biomm as a key advancement in their plan to extend their presence beyond the US and Europe for Peptides, according to a statement. He also highlighted that this aligns with their growth strategy of introducing a range of intricate GLP-1 drug-device combination products to the market.

Mittal expressed assurance that partnering with Biomm will offer improved access to advanced and high-quality treatment options for diabetes patients in Brazil, aiding them in better disease management, according to a statement.

According to Biomm CEO Heraldo Marchezini, Brazil has the fifth highest diabetes incidence in the world, with 16.8 million adults aged 20 to 79 years suffering from the disease and an estimated 21.5 million cases by 2030, according to the International Diabetes Federation’s Diabetes Atlas (IDF).

Mittal further stated that they have prioritized forming strategic partnerships to broaden access to advanced treatments for diabetes and improve people’s quality of life.

According to the IQVIA MAT data, the total addressable market opportunity for Semaglutide in Brazil is around USD 580 million.

At around 10.48 AM, Biocon was trading 2.26% higher at ₹269.70, against the previous close of ₹263.75 on NSE. The counter rose to an intraday high of ₹273.

For feedback and suggestions, write to us at editorial@iifl.com

Related Tags

  • Biocon
  • Biocon Agreement
  • Biocon news
  • Biocon share price
  • Biocon Updates
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More

Most Read News

Indian markets close on a positive note
14 Jun 2024|06:41 PM
Sensex and Nifty Surge
14 Jun 2024|06:43 PM
LIC stock price up by more than 5% today
14 Jun 2024|06:44 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.